AstraZeneca prevails in GSK royalties row at UK High Court
Feud involved a blockbuster cancer drug belonging to a family of PARP inhibitors | GSK unit failed to persuade the court of the merits of its ‘certain uses’ argument.
AstraZeneca has secured a victory after the High Court of England and Wales ruled that it was owed royalties relating to the ovarian cancer drug Zejula (Niraparib).
In a decision handed down on Wednesday April 5, the court held that GlaxoSmithKline’s (GSK) subsidiary, Tesaro, was liable for the payments resulting from the sales of the blockbuster treatment.
GSK acquired Tesaro 11 years ago, including the rights to the drug that is part of a family of PARP inhibitors, which interfere with certain enzymes that can help develop cancer cells.
Exclusive rights
The dispute emerged when AstraZeneca sued GSK in 2021, demanding a larger chunk of the sales from Zejula.
In 2012, Tesaro signed a licensing contract agreement with AstraZeneca, which gave it exclusive rights to certain methods of treating patients with Zejula.
During the proceedings,Tesaro countered that it should only pay royalties concerning the uses specifically referred to by the licensed patents.
But Justice David Richards rejected this point of view, holding that Tesaro owed royalties on all net sales of Zejula in each country in which it holds licensed patents.
In his conclusion, he pointed out that there was no suggestion that Tesaro has been selling Zejula for a purpose that includes anything other than as a treatment for cancer.
“In those circumstances, putting together all inferences, including those drawn from the wording of the licence agreement…I have reached the conclusion that AZ’s answer…is to be preferred. Tesaro is obliged to pay AZ royalties on all net sales of Zejula in each country in which there are licensed patents from the first commercial sale in that country.”
According to a report in Reuters, Zejula sales in 2022 reached £463 million ($578 million).
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk